Cocrystal Pharma

Tucker, United States Founded: 2007 • Age: 19 yrs Listed
Small molecule therapeutics for viral diseases are developed.

About Cocrystal Pharma

Cocrystal Pharma is a publicly listed company based in Tucker (United States) founded in 2007. Small molecule therapeutics for viral diseases are developed. Cocrystal Pharma has raised $45.06 million across 19 funding rounds. The company has 11 employees. Cocrystal Pharma offers products and services including Influenza A Oral PB2 Inhibitor CC-42344, Norovirus Oral Pan-viral Protease Inhibitor CDI-988, Influenza A Inhaled PB2 Inhibitor CC-42344, Norovirus Replication Inhibitors, and Respiratory Viruses Pan-viral Inhibitors. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is COCRYSTAL PHARMA, INC. Its competitors include Eiger BioPharmaceuticals, Aligos Therapeutics and AusperBio; 3 of its 3 listed competitors have raised funding.

Company details

Cocrystal Pharma is discovering and developing small molecule therapeutics for serious andor chronic viral diseases. It utilizes its proprietary technology that provides the unique 3-D structure of inhibitor complexes at a near-atomic resolution that helps in identifying novel binding sites. Its drug pipeline includes CC-31244, a non-nucleoside inhibitor (NNI) for the treatment of Hepatitis C infection (Phase 1); CC-2850, a nucleoside prodrug for the treatment of Hepatitis C infection (Preclinical); CC-2069, an NS5A inhibitor for the treatment of Hepatitis C infection (Preclinical). The company also has programs for Influenza and Norovirus.

  • Headquarters Tucker, United States
  • Employees 11
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website cocrystalpharma.com
  • Social LinkedIn X Facebook
  • Legal Name Cocrystal Pharma, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$8.83 M (USD)
    49.55
    as on Dec 31, 2025
  • EBITDA
    -$8.64 M (USD)
    51.31
    as on Dec 31, 2025
  • Total Equity Funding
    $45.06M (USD)

    in 19 rounds

  • Latest Funding Round
    $3M (USD), Post-IPO

    May 2017

  • Employee Count
    11

Products & Services of Cocrystal Pharma

Cocrystal Pharma offers a comprehensive portfolio of products and services, including Influenza A Oral PB2 Inhibitor CC-42344, Norovirus Oral Pan-viral Protease Inhibitor CDI-988, Influenza A Inhaled PB2 Inhibitor CC-42344, Norovirus Replication Inhibitors, and Respiratory Viruses Pan-viral Inhibitors.

Influenza A Oral PB2 Inhibitor CC-42344
Antiviral Drug

Inhibits influenza A virus replication for treatment of respiratory infections.

Norovirus Oral Pan-viral Protease Inhibitor CDI-988
Antiviral Drug

Targets norovirus and coronaviruses to prevent viral replication.

Influenza A Inhaled PB2 Inhibitor CC-42344
Antiviral Drug

Provides inhaled treatment for influenza A through replication inhibition.

Norovirus Replication Inhibitors
Antiviral Drug

Develops compounds to block norovirus replication in gastroenteritis cases.

Respiratory Viruses Pan-viral Inhibitors
Antiviral Drug

Inhibits replication of various respiratory viruses for broad-spectrum use.

Funding Insights of Cocrystal Pharma

Cocrystal Pharma has successfully raised a total of $45.06M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $45.06M
  • Total Rounds 19
  • Last Round Post-IPO β€” $3M
  • First Round $7.68M

    (Oct 2009)

Latest 10 of 19 funding rounds of Cocrystal Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2017$3MPost-IPO––
–
Sep 2016$4.01MPost-IPO––
–
Mar 2016$5MPost-IPO––
–
Jan 2014$2.75MSeries C––
–
Nov 2013$3.5MSeries C––
–
Oct 2013$7.5MSeries C––
–
Apr 2013$800,000Series B––
–
Jun 2012$200,000Debt – Conventional––
–
Apr 2012$2.25MSeries B––
–
Apr 2012$250,000Series B––
–

People of Cocrystal Pharma

9 people are tracked at Cocrystal Pharma (4 in leadership, 5 in board & advisors); the tracked headcount is 11.

NameRoleGroup
Sam Lee
Interim Co-CEO & PresidentLeadership
Marie-Laure Crouch
Director Of Programs And Project ManagementLeadership
William Ollinger
Vice PresidentLeadership
James J. Martin
Co-ceo And CFOLeadership
Anthony Japour
DirectorBoard & advisors
Roger Kornberg
ChairmanBoard & advisors
Phillip Frost
DirectorBoard & advisors
Richard C. Pfenniger, Jr.
DirectorBoard & advisors
Steve Rubin
Vice ChairmanBoard & advisors
Premium access

Complete people profiles for Cocrystal Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Cocrystal Pharma

Cocrystal Pharma is a publicly listed company on the NASDAQ with ticker symbol COCP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 Aug 2015
  • Listed onNASDAQ: COCP
  • Listed entityCocrystal Pharma, Inc.
  • Exchange sectorHealth technology
  • ISINUS19188J4094
  • Share price$1.08 (+1.89% on the day) · 2026-10-13
  • Market capitalisation$20.8M
  • EPS (diluted, trailing year)$-0.76
  • Volume (last session)86,702

Financials of Cocrystal Pharma

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$8.8M-$8.6M
2024-$17.5M-$17.8M
2023-$18.0M-$22.6M
2022-$38.8M-$17.8M
2021-$14.2M-$13.8M
Premium access

Detailed financial statements for Cocrystal Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Cocrystal Pharma

4 dated milestones of Cocrystal Pharma across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cocrystal Pharma is founded.
  2. Funding First funding round of $7.7M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $3.0M.

Competitors of Cocrystal Pharma

Cocrystal Pharma has 3 listed competitors in our database, 3 of them funded. They include Eiger BioPharmaceuticals, Aligos Therapeutics and AusperBio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
eigerbio.com2000San Carlos, United States$8.9M56
Developer of antiviral agents against targets in the treatment of hepatitis
aligos.com2018San Francisco, United States$225M70
Developer of therapies to treat hepatologic diseases and viral infections
ausperbio.com2019San Mateo, United States$223M
Therapies for chronic hepatitis B and infectious diseases are developed.
Premium access

Detailed competitors of Cocrystal Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Cocrystal Pharma

The website of Cocrystal Pharma (cocrystalpharma.com) receives about 2.9K visits a month and ranks #6,117,909 among all websites worldwide, #6,425 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    2.9K

    ▲ 1.5% vs previous month

  • Unique visitors
    1.2K

    per month

  • Global rank
    #6,117,909

    among all websites

  • Category rank
    #6,425

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Cocrystal Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
eyepointpharma.com
100%
3.9K#3,819,866View details

Top companies in Infectious Diseases

3 companies that operate in the same segment as Cocrystal Pharma (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cocrystal Pharma

Premium access

Complete news archive for Cocrystal Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cocrystal Pharma

Cocrystal Pharma was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Cocrystal Pharma is headquartered in Tucker, United States. It is registered at Tucker, Georgia, United States.

Cocrystal Pharma is a funded company, having raised a total of $45.06M across 19 funding rounds to date. The company's 1st funding round was a Series B of $250K, raised on Oct 2009.

Cocrystal Pharma has 11 employees.

Cocrystal Pharma is discovering and developing small molecule therapeutics for serious andor chronic viral diseases. It utilizes its proprietary technology that provides the unique 3-D structure of inhibitor complexes at a near-atomic resolution that helps in identifying novel binding sites. Its drug pipeline includes CC-31244, a non-nucleoside inhibitor (NNI) for the treatment of Hepatitis C infection (Phase 1); CC-2850, a nucleoside prodrug for the treatment of Hepatitis C infection (Preclinical); CC-2069, an NS5A inhibitor for the treatment of Hepatitis C infection (Preclinical). The company also has programs for Influenza and Norovirus.

Cocrystal Pharma's top competitors include Eiger BioPharmaceuticals, AusperBio and Aligos Therapeutics.

Cocrystal Pharma offers Influenza A Oral PB2 Inhibitor CC-42344, Norovirus Oral Pan-viral Protease Inhibitor CDI-988, Influenza A Inhaled PB2 Inhibitor CC-42344, Norovirus Replication Inhibitors, and Respiratory Viruses Pan-viral Inhibitors.

Yes, Cocrystal Pharma is publicly traded on NASDAQ under the ticker symbol COCP.

Cocrystal Pharma operates through Cocrystal Pharma, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available